Subsequent studies using cancer cells having a stable knockdown or overexpression of PGRMC1 challenged these conclusions since neither condition resulted in a change in binding of the σ2R radioligand, [3H]DTG17,18. This evidence concerns the gene PGRMC1 and cancer.